ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Nitric oxide synthase inhibitors reduce the formation of neutrophil extracellular traps and alleviate airway inflammation in the mice model of asthma.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of Nasal Nitric Oxide in the Diagnosis of Epithelial Remodeling Types of Nasal Polyps.Turkish archives of otorhinolaryngology · 2026Article
- Dietary live microbe intake and asthma risk and mediator analysis: a cross-sectional study of NHANES 2003-2018.BMC pulmonary medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Asthma, a widespread chronic inflammatory disease can contribute to different degrees of lung function damage. The objective of this study is to explore the potential effects of nitric oxide synthase (NOS) inhibitors in asthma using mice model induced by ovalbumin (OVA). BALB/c mice were treated with OVA to establish an asthma model. Mice were intranasally challenged with different NOS inhibitors and analyzed the impact of NOS inhibitors on the lung tissues and bronchoalveolar lavage fluid (BALF). Histopathological analysis was performed by Periodic Acid-Schiff (PAS) staining. Airway reactivity was assessed using methacholine challenge testing. The concentrations of nitric oxide (NO), Neutrophil extracellular traps (NETs), and cytokines were determined by enzyme-linked immunosorbent assay (ELISA) assay. NOS inhibitors effectively improved airway inflammation and reduced airway hyperresponsiveness. In addition, NOS inhibitors decreased the concentrations of NO, NETs, and inflammation in the airway and BALF. The decreased NO production and reduced NET formation in the lung indicate that NOS inhibitors inhibit the process of NET release to alleviate asthma.
Indexed as
Identifiers
39878819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.